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Introduction  
Therapeutic complement inhibition was first introduced in Paroxysmal Nocturnal Hemoglobinuria 
(PNH) in 2002 with the first complement inhibitor eculizumab, a humanized anti-C5 monoclonal 
antibody (mAb)1 registered in 2007. Ten years later, irrespective of the enthusiastic efforts from 
academicians and pharmaceutical companies aiming to develop novel complement inhibitors, no 
additional anti-complement agent has been approved. Indeed, the treatment of PNH has been 
revolutionized by eculizumab: since the pioneering experience, it became evident that therapeutic 
inhibition of C5 resulted in sustained inhibition of intravascular hemolysis typical of PNH, eventually 
resulting in a major clinical improvement.2 The two subsequent phase III registration trials 
demonstrated a dramatic reduction of intravascular hemolysis, which led to hemoglobin stabilization 
and transfusion independency in about half of patients.3,4 This remarkable clinical effect was obtained 
without major safety concerns, including the feared risk of infectious complications (all patients on 
eculizumab receive broad vaccinations against N. Meningitidis).3-5 Furthermore, in addition to the 
control of all hemolysis-related symptoms and to improved quality of life, sustained inhibition of 
terminal complement resulted in a marked reduction of the thromboembolic events typical of PNH.5 
The long-term use of eculizumab in PNH is more than a supportive treatment, since it has been 
demonstrated that it largely affects the natural history of the disease. Indeed, two independent studies 
have clearly demonstrated that the survival of PNH patients on eculizumab exceeds 90% at 5 years,6,7 
which is by far higher than what known from previous natural history data.8,9 Thus, eculizumab is the 
current gold standard for PNH patients presenting with hemolytic and/or thromboembolic disease 
(while those with meaningful bone marrow failure should follow treatment algorithm of aplastic 
anemia).10,11 
Nevertheless, PNH is not cured by eculizumab, since the only curative option for PNH remains 
hematopoietic stem cell transplantation;12 and, irrespective of the remarkable impact of anti-C5 
treatment on survival and disease manifestations, some unmet clinical needs emerged in the era of 
eculizumab. Three major unmet needs can be identified: i. limited access to current anti-complement 
treatment due to elevated cost (eculizumab is not approved in vast areas of the world, and even where it 
is approved the indications to treatment are somehow restricted to more ill patients); ii. heaviness of 
life-long bi-monthly intravenous infusion; iii. insufficient clinical benefit, usually in terms of residual 
anemia. While the first two points may have a limited scientific interest, the discussion of suboptimal 
clinical hematological response to eculizumab represents the main driver to develop novel strategies of 
therapeutic complement inhibition. True resistance to eculizumab treatment has been documented only 
in a few patients, mostly of Japanese ethnicity, carrying an inherited polymorphism of C5;13 for these 
patients at the moment there is no available treatment. However, even in patients with clear evidence of 
effective complement blockade (as documented by lactate dehydrogenase [LDH] level), the 
hematological benefit is quite heterogeneous, and residual anemia pertain to about two thirds of PNH 
patients on eculizumab, with about one third still requiring red blood cell transfusions.3,4,14-16 The most 
obvious cause of residual anemia during eculizumab is inadequate compensatory erythropoiesis due to 
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concomitant aplastic anemia. Indeed, even in patients with hemolytic PNH, bone marrow failure is 
possible at any time during the disease course, due to the well-established overlap between AA and 
PNH;17-19 these patients should receive the appropriate treatment according to the AA 
algorithm.10,11,20,21 However, the vast majority of PNH patients on eculizumab remain anemic 
irrespective of increased reticulocyte count, eventually documenting residual hemolysis even during 
anti-C5 treatment. It is now well accepted that in 15-20% of patients this is due to residual intravascular 
hemolysis which regularly occurs 1-2 days before the next dosing of eculizumab (the so-called 
“pharmacokinetic breakthrough”).16 Furthermore, a “pharmacodynamic breakthrough” has been 
described, which accounts for lack of LDH normalization in most patients (i.e., as a marker of low-
grade continuous intravascular hemolysis), as well as for possible hemolytic paroxysms in 
concomitance with infectious episodes (or any other event) triggering a massive complement 
activation.22,23 For patients with pharmacokinetic breakthrough either the increase of eculizumab dose 
to 1200 mg or the reduction of the dosing interval to 10 days have been proven somehow effective.24 
However, the most common cause of residual anemia in PNH patients on eculizumab has been 
identified in C3-mediated extravascular hemolysis. This phenomenon, which is never seen in untreated 
PNH patients and unmasked by eculizumab treatment, mechanistically pertains to most PNH patients 
on eculizumab as a result of upper (upstream C5) complement activation, which remains uncontrolled 
irrespective of C5 blockade.25 As a result, progressive deposition of C3 fragments on PNH erythrocytes 
sparing terminal complement-mediated lysis eventually leads to chronic extravascular hemolysis.25-28 
While C3 opsonization has been confirmed by several groups,25,29,30  the actual clinical relevance of 
extravascular hemolysis has not been fully acknowledged by all experts;7 nevertheless, C3-mediated 
extravascular hemolysis impairs hematological response to eculizumab in 25-50% of patients.7,25,29,30 
The reasons accounting for such heterogeneous clinical weight remain to be elucidated, even if a 
possible role for genetic variants of complement-related genes has been postulated and already 
reported, for instance, for the hypomorphic variant of complement receptor 1 (CR1) gene.31 While the 
use of steroids is discouraged,27  splenectomy has been anecdotically reported effective to treat C3-
mediated extravascular hemolysis;32,33 however, at the moment there is no reliable treatment option for 
this common event emerging during eculizumab treatment.34 
 
Novel strategies of complement inhibition 
 The unmet clinical needs described above, together with a growing financial interest driven by 
the high price of current anti-complement treatment, have triggered the development of novel 
complement inhibitors. A plethora of agents is currently in the pipeline of several pharmaceutical 
companies (Table 1);35 they can be divided in two major categories, according to their mechanism of 
action. The first category exploits novel agents targeting C5 (similarly to eculizumab), while the second 
one pioneers the possibility of intercepting the complement cascade upstream, at the level of its 
initiating activation steps. 
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Novel inhibitors of C5  
 Giving the excellent safety and efficacy of eculizumab, C5 remains a good target for developing 
alternative agents blocking the terminal complement effector pathway. Novel C5 inhibitors include 
anti-C5 mAb, as well as different classes of compounds. In addition to the eculizumab biosimilar ABP 
959 developed by AMGEN,36 there are at least five additional anti-C5 mAb in clinical or preclinical 
development. ALXN1210 and ALXN5500 are two anti-C5 mAb with longer half-life, potentially 
available even for subcutaneous injections, developed by Alexion; they share with eculizumab the same 
C5 target epitope. The leading compound ALXN1210 has been granted with orphan designation by 
FDA; a phase I study in healthy volunteers demonstrated immediate, complete, and sustained C5 
inhibition, with a terminal half-life about four-fold longer than eculizumab.37 Another humanized anti-
C5 mAb with long half-life is named SKY59 (also known as RO7112689), and it is in development by 
Roche. SKY59 has a pH-dependent binding to a different epitope of C5, which leads to a continuous 
recycling eventually accounting for its very long half-life.38 In a preclinical model, SKY59 was shown 
effective in suppressing C5 function and complement activity (even on the Japanese C5 variant 
p.Arg885His) for a significantly longer duration compared to conventional mAb.38 Novartis is also 
developing a fully human anti-C5 mAb named LFG316; this agent, initially developed for ophthalmic 
indications, is now under investigation for PNH within a proof of concept study enrolling patients in 
Japan.39 The list of mAb-based C5 inhibitors also includes an engineered derivative exploiting the Ab 
fragment of an anti-C5 mAb; this minibody called Mubodina is in development by Adienne Pharma & 
Biotech,40,41 but so far no trial for PNH has been started. 
 Therapeutic C5 inhibition is not limited to anti-C5 mAb; indeed, different strategies exploiting 
non-Ab molecules have been exploited. The most elegant and novel strategy exploits a small 
interfering RNA (siRNA) duplex specific for C5, which is able to completely silence C5 production 
from the liver in an animal model.42 This compound, developed under the name of ALNCC5 by 
Alnylam, has been proven safe and effective in a phase I trial in healthy individuals (n=32), resulting in 
>99% reduction of C5 plasma level and >95% inhibition of serum complement activity.43 ALNCC5 has 
been already investigated in proof of concept studies for PNH, as discussed below. Two additional non-
Ab anti-C5 compounds are currently under investigation in PNH. Coversin (also known as OmCI) is a 
16 kDa protein of the lipocalin family derived from the tick Ornithodoros moubata.44,45 Coversin is able 
to prevent C5 cleavage by its convertases,44,45 and its in vitro efficacy in PNH has been already 
documented,46 even in patients carrying C5 polymorphisms.47 In a phase I study in healthy volunteers, 
coversin was shown bioavailable after subcutaneous injections, with excellent PK and PD in absence of 
immunogenicity and of other safety concerns.45 Akari is currently performing clinical studies 
investigating this agent in PNH patients. Finally, a small macrocyclic peptide named RA101495 has 
been developed by RApharma.48 This is a small, cyclic, peptide-like polymer of the class of 
cyclomimetics which is produced by ribosomal synthesis of unnatural peptides, and harbors excellent 
cell permeability, stability, potency, and bioavailability.48,49 RA101495 has been shown to inhibit 
hemolysis in an in vitro model of PNH,49,50 and a clinical translation program for PNH is ongoing. A 
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number of alternative technologies have been exploited to develop newer classes of compounds (e.g., 
aptamers, SOMAmers, affibodies)35 with high specificity for C5; however, since they are in early stage 
of clinical development, they are not discussed in this manuscript. 
Inhibitors of early steps of complement activation  
 The concept that the inhibition of early steps of complement activation might be beneficial in 
PNH rose from the initial description of C3-mediated extravascular hemolysis,15 and took advantage 
from preclinical researches done in other fields of medicine.51-53 C3 cleavage by C3 convertases is the 
key event in complement activation and may occur along one of the three different complement 
activating pathways – classical (CCP), alternative (CAP) and mannose/lectine (CMP) ones. Indeed, any 
initial complement activation merges at the level of C3, and eventually leads to C5 cleavage and to the 
activation of the harmful terminal effector mechanisms. Given that each complement pathway exploits 
different proteins, inhibitors of early complement activation may be divided in two groups: i. broad 
inhibitors of C3 and ii. pathway-specific inhibitors of initiating events (see Table 2 and Figure 1). Here 
we’ll focus only on agents potentially effective for PNH, which includes C3 inhibitors and CAP 
inhibitors (the role of CCP and CMP in the pathophysiology of PNH is considered somehow limited, 
even if experimental evidences are lacking). 
 Direct inhibition of C3 has been postulated, but it is challenging because of the very high 
plasma level of C3 (~1 mg/mL). Indeed, mAb specific for native C3 have not been developed; a 
mAbselectively targeting the activated C3 fragments C3b and iC3b (3E7, and its de-immunized 
derivative H17) has been investigated in PNH in vitro, showing prevention of both hemolysis and C3 
opsonization of PNH erythrocytes.54 However, these anti-C3b/iC3b mAb (which eventually work as 
selective CAP inhibitors) cannot be used in PNH as they are due to expected worsening of 
extravascular hemolysis through the Fc receptor; further derivatives of these mAb exploiting Fab 
fragments for therapeutic purpose are still in preclinical investigation.55 Thus, therapeutic inhibition of 
C3 is mostly exploited using small peptide inhibitors, namely the 13-residue disulfide-bridged 
peptidecompstatin and its derivatives.56 Compstatin is a broad complement inhibitor which binds to 
human (and all primate) C3 and C3b, preventing C3 cleavage and C3b incorporation in C3/C5 
convertase.57,58 Thus, compstatin and its derivatives completely abrogate complement activation along 
all the three activating pathways CCP, CAP and CMP; these molecules also disable the CAP-mediated 
amplification loop.57,58 The spectrum of compstatin analogs is growing, with improved PK and PD 
properties which may facilitate therapeutic application;59,60 both first and second generation compstatin 
derivatives have been proven effective in PNH in vitro, showing excellent control of hemolysis and of 
C3 opsonization.61,62 
 In addition to molecules targeting C3, therapeutic complement inhibition in PNH may aim to 
intercept the activation through the CAP; the two  main strategies of CAP inhibition exploit engineered 
proteins based on endogenous regulators of complement activation, as well as small inhibitors of key 
components of CAP.35 CR1 and CFH are endogenous negative regulators of complement which both 
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act as: i. co-factor of complement factor I for C3b inactivation;63 ii. and prevention of formation and 
acceleration of decay of C3 convertase (for CFH, only CAP convertase).64,65 Given their pleiotropic 
effects on complement regulation, these endogenous inhibitors have been exploited for therapeutic use 
through the generation of engineered proteins with targeted inhibitory properties.66 The first agent of 
this class is TT30, a 65 kDa engineered protein consisting of the functional domain of CFH merged 
with the iC3b/C3dg-binding domain of complement receptor 2 (CR2).67 The activity of TT30 in PNH 
has been investigated in vitro, showing complete abrogation of intravascular hemolysis and C3 
fragment deposition of PNH erythrocytes.68 Based on this data, TT30 has entered its clinical translation 
in PNH.69 CFH-based inhibitors have been developed also through the generation of miniaturized 
versions fusing the inhibitory domain and the C3-binding domain of CFH;70 as TT30, mini-FH 
prevents hemolysis and C3 opsonization of PNH erythrocytes in vitro.70 Inhibitors based on CR1 have 
been developed too;35 mirococept (APT070) is an engineered version of CR1 specifically designed for 
incorporation in cell membranes,71,72 which is now in clinical development for kidney 
transplantation.73,74 The possible role of CR1-based inhibitors in PNH is somehow supported by the 
clinical observation that PNH patients carrying the hypomorphic variant of CR1 have a worse clinical 
response to eculizumab in vivo, and exhibit more pronounced C3 deposition both in vitro and in vivo.75  
 The latest strategy of selective inhibition of CAP is based on inhibitors of complement factor B 
(FB) and complement factor D (FD), the two key molecules of the complement activation along the 
alternative pathway; inhibitors of properdin have been postulated as well.76 Even if antibody-based 
inhibitors have been considered, the most recent class of compound include small molecules specific 
for either FD or FB. Potent and selective anti-FD agents have been developed by Novartis;77 all these 
compound in vitro prevent hemolysis and C3 opsonization of PNH erythrocytes.78 Anti-FD small 
molecules have been developed also by Achillion (ACH-3856, ACH-4100, ACH-4471), with similar 
potential activity in PNH in vitro.79,80 Notably, all these anti-FD small molecules are bioavailable after 
oral administration.78,79 Furthermore, CAP inhibitors developed by Novartis also include small 
molecules targeting FB;81 these orally bioavailable anti-FB small molecules share with anti-FD agents 
the in vitro activity on PNH erytnrocytes.82 Both anti-FD and anti-FB have entered their clinical 
development, and clinical trials for PNH patients have started. 
 
Clinical translation: status of art and anticipated results  
 Many of the agents described above have started their clinical development for the treatment of 
PNH; here we’ll summarize publically available information, describing the ongoing trials with their 
design and preliminary data (when available), or results anticipated by their mechanism of action. 
ABP 959 (Amgen) 
 The anti-C5 mAb ABP 959 has been initially tested in Australia in a phase I randomized trial 
investigating PK and PD of this compound as compared to eculizumab (ACTRN12616000509460).83 
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Data are not publically available yet; nevertheless, a large phase III randomized trial is currently 
ongoing in Europe (EudraCT Number 2017-001418-27).36 Since this compound has been announced as 
a biosimilar of eculizumab (even if the true meaning of this term may be questioned until details about 
drug manufacturing will be available), safety and efficacy profile should parallel those of eculizumab, 
and no further scientific discussion about ABP 959 is provided. 
ALXN1210 (Alexion)  
 ALXN1210 has been already tested in two phase I/II trials enrolling untreated PNH patients 
(NCT02598583 and NCT02605993) aiming to evaluate safety, tolerability, and efficacy of two 
different intravenous (IV) dosing regimens of ALXN1210.84,85 No deaths, serious adverse events, drug 
discontinuations, or adverse event (AE) leading to withdrawals were recorded.86 The interim analysis 
of these studies demonstrated rapid, complete, and sustained C5 inhibition, eventually leading to 
prompt and sustained LDH reduction and frequent hemoglobin stabilization in all treatment cohorts;86 
these results have just been updated.87 The two studies enrolled 13 and 26 patients, respectively. 
Patients receiving 600 and 900 mg as loading dose, followed by maintenance with 1800 mg every 4 
weeks, showed the best outcome in terms of sustained control of intravascular hemolysis, as 
demonstrated by LDH reduction (with normalization in 6/7) and no breakthrough episode.87 Notably, 2 
out of 39 patients on ALXN1210 experienced N. Meningiditis infections presenting as sepsis;87 both 
patients completely recovered after ceftriaxone treatment, and continued the ALXN1210 treatment 
within the study.87 These results represented the background to design the two large phase III trials 
which are now comparing ALXN1210 used at 3300 mg every 8 weeks (maintenance dose, after a 
loading dose of 2700 mg) with the standard treatment eculizumab both as initial treatment for PNH,88 
as well as switch therapy for patients already on eculizumab with adequate control of hemolysis (LDH 
<1.5x ULN).89 Notably, in both studies changes in LDH levels appear as primary endpoint, likely 
because of a possible deeper inhibition of terminal effector complement with ALXN1210 (as suggested 
by larger reduction of LDH),87 which may result in a better control of chronic intravascular hemolysis 
(e.g., less PK and/or PD breakthrough). Whether this more profound complement inhibition may affect 
the risk of infectious complications (i.e., the actual incidence of N. Meningiditis infections needs to be 
evaluated carefully;87 low-level residual C5 activity demonstrated with eculizumab23 might be 
somehow protective from infections), as well as the clinical meaning of this better control of 
intravascular hemolysis will be answered by experimental data expected by late 2018. Nevertheless, the 
most obvious benefit from this long-lasting C5 inhibitor will pertain to patients’ compliance, as a result 
of the two-month dosing interval (even if still IV). The more profound C5 inhibition might also 
anticipate some benefit in patients experiencing frequent breakthrough, but at the moment this 
population was excluded from the ongoing trials. 
SKY59/RO711268 (Roche) 
 This other long-lasting anti-C5 mAb is currently under investigation within a phase I/II study 
(NCT03157635)90 consisting of 3 sequential parts and an open-label extension; safety, tolerability, PK, 
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and PD of single-doses of RO7112689 were initially evaluated in healthy volunteers during part I. 
Then, part 2 and 3 included untreated and eculizumab-treated PNH patients, respectively, aiming to 
evaluate safety, tolerability, PK, PD and efficacy of RO7112689 in PNH.90 Thus, this complex study 
merged in one trial different phases of clinical investigation, which could have been performed 
separately to better allow possible changes in treatment schedule and/or other protocol details. 
Nevertheless, this program has completed the first two parts of the study; even if data are not yet 
publically available, they eventually supported the starting of part 3 of the trial. In this part PNH 
patients will receive a loading IV dose of RO7112689 on Days 1, followed by SC administration of 
RO7112689 at different doses and schedule. To be included in the trial PNH patients must be on stable 
doses of eculizumab for at least three months; the primary endpoint of the study is PD of RO7112689, 
as measured by LDH and complement activity assays. Here the anticipation is that this molecule, once 
the right schedule is identified, should parallel excellent efficacy and safety of eculizumab, with 
possible advantage in terms of patients’ compliance due to SC administration (also depending on dose 
interval). Detailed PD data will tell whether, as anticipated for ALXN1210, RO7112689 may also 
deliver a deeper C5 inhibition eventually preventing meaningful breakthrough. Since RO7112689 
recognizes an epitope different from that bound by eculizumab, it should address the problem of 
genetic resistance to eculizumab.13,38 
LFG316 (Novartis) 
A proof of concept phase I study is currently investigating LFG316 in untreated PNH patients; the 
primary endpoint of the study is biological efficacy, as measured by LDH change.39 This study, which 
is performed mostly in Japanese centers, will likely represent an option for patients carrying C5 
polymorphisms associated with intrinsic resistance to eculizumab.13  
ALNCC5 (Alnylam) 
The phase I/II first-in-human trial with ALNCC5 also included an arm enrolling PNH patients;91 
preliminary data were presented at ASH 201592 and updated at ASH 2016.93 Six patients received 
ALNCC5 at weekly doses (200 or 400 mg, SC), 3 in monotherapy (untreated patients) and 3 on top of 
fortnightly eculizumab (one with persistent breakthrough irrespective of increased dose up to 1200 
mg). No severe AE was observed, nor AE requiring treatment discontinuation; one patient developed 
increased transaminases, possibly related to the drug (or to liver damage and/or hemolysis secondary to 
concomitant infection).92,93 In untreated patients, ALNCC5 resulted in C5 knockdown >98% (as 
previously seen in healthy individuals).43 Nevertheless, LDH reduction (37% and 50%) was observed 
only in 2 of 3 patients with very high baseline LDH (>5x ULN); residual low-level hemolysis with 
LDH >1.5x ULN remained in all 3 patients.92,93 This was consistent with data using C5-depleted sera in 
an in vitro model of PNH,61,68 where the addition of recombinant C5 in amount as low as 0.9 µg/mL 
(equal to about 1% of normal C5 plasma level) restored >90% of the complement-mediated hemolytic 
activity (Risitano et al, unpublished observation). Nevertheless, these PNH patients treated in 
monotherapy with ALNCC5 then benefited from the addition of eculizumab, which resulted in full 
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control of residual intravascular hemolysis at doses as low as about 25% of standard ones (600 mg 
monthly).92,93 The potential efficacy of a combined treatment with ALNCC5 and eculizumab was also 
investigated in the 3 patients already on eculizumab; indeed, combined treatment resulted in LDH 
normalization, even in the patients experiencing breakthrough (who was able to reduce eculizumab at 
the standard schedule of 900 mg every other week).92,93 Based on these data, the best setting for further 
development of ALNCC5 in PNH is in combination with eculizumab, to improve response in poor 
responders;94 this combination therapy may also represent an option to achieve deeper control of 
residual intravascular hemolysis, and/or reduce the dosing of eculizumab (cost-effectiveness of this 
strategy can be drawn only knowing the price of ALNCC5).  
Coversin (Akari) 
Coversin is currently under investigation in PNH within different phase II trials;95,96 the first proof of 
efficacy of coversin was shown in PNH patients resistant to eculizumab.95 Subsequently, coversin was 
investigated in a global phase II study (COBALT) which exploited SC coversin at a fixed initial dose 
of 60 mg followed by bi-daily doses (15-30 mg) for 28 days and then 30 mg daily for additional two 
months.96 Data are available for the first 5 untreated PNH patients enrolled;97 four of them remained on 
coversin (one was withdrawn because of possible co-morbidity). Coversin was well tolerated, with 
mild injection site reactions as only AE; no high-titer neutralizing antibodies were demonstrated. LDH 
reduction was observed in all patients, even if only two of them reached the primary endpoint of the 
study (LDH <1.8x ULN); irrespective of this residual hemolysis, no red cell transfusion was needed 
during the three-month period of the study.97 According to authors’ conclusions, this residual 
intravascular hemolysis is not related to sub-therapeutic plasma levels of coversin, since terminal 
complement activity as assessed by CH50 remained fully inhibited along the study.97 These data 
demonstrate that coversin has biological efficacy in PNH, with acceptable safety profile, and the 
benefit of possible self-administration; nevertheless, likely the treatment regimen may be optimized 
(with the current schedule residual intravascular hemolysis is quite frequent), and the concerns about 
possible neutralizing antibody requires further investigations.  
RA101348 (RApharma) 
Rapharma is developing a groups of anti-C5 small macrocyclic peptides,49 including some orally 
bioavailable agents;98 the lead compound RA10149550 was investigated in a phase I study in healthy 
volunteers.99 RA101495 was safe and well tolerated as SC injections in healthy volunteers, with only 
mild local irritation;99 a daily dosing allowed full and sustained suppression of complement activity 
(>95%).100 Based on these data, two parallel phase II study were started: study NCT03078582 
investigated a loading dose of 0.3 mg/kg followed by 0.1 mg/kg daily in both untreated and 
eculizumab-treated PNH patients (these latter switched to RA101495).101 The second study 
NCT03030183 rather investigated the same treatment regimen in PNH patients with inadequate 
response to eculizumab, defined as LDH >1.5x ULN.102 The primary endpoint of both study is LDH 
change; data from these trials are still pending. Based on preclinical work, it is expected that biological 
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and even clinical efficacy in terms of control of intravascular hemolysis are seen, since an extension 
study for patients enrolled in any of the initial study has been launched.103 
TT30 (Alexion) 
TT30 was the first second-generation complement inhibitor tested in vivo in PNH patients; indeed, a 
single ascending dose, phase I study was started in 2011 and a total of 10 untreated PNH patients were 
enrolled to investigate tolerability, PK, PD, and immunogenicity of two different formulations of TT30 
(ALXN1102 and ALXN1103) given as single IV infusion or SC injection (NCT01335165).69 
Preliminary results from this study ws presented at ASH 2015:104 TT30 was safe and well tolerated, 
with no dose-related safety concern; no immunogenicity was observed. Initial PK and PD data 
demonstrate that TT30 may achieve pharmacological levels able to inhibit the CAP; this inhibition may 
result in transient LDH decrease, eventually proving the concept of possible therapeutic efficacy of 
CAP inhibitors in PNH.104 However, the short half-life of the compound in its current form precluded 
further clinical development of TT30 in its current form, and this program was stopped.104 
AMY-101 (Amyndas)  
 AMY-101/Cp40 is a last generation compstatin analog with increased inhibitory potency and 
better PK profile,60 which has been proven effective in vitro to inhibit lysis and C3 fragment 
opsonization of PNH erythrocytes;61 thus, this is an excellent candidate which anticipates to prevent 
both intravascular and C3-mediated extravascular hemolysis of PNH.61 The potential therapeutic 
benefit of AMY-101 over standard anti-C5 treatment has been recognized by medicines agencies from 
both Europe (EMA) and US (FDA), who recently granted Orphan Drug designation to AMY-101 for 
the treatment of PNH.  After pre-clinical investigations in non-human primates,105 a phase I single and 
multiple ascending dose study investigating safety, PK and PD of AMY-101 in healthy volunteers has 
been completed.106 Even if data have not been presented yet, Amyndas has announced a translation 
program for PNH which includes two separate phase II trials investigating the efficacy of  a therapeutic 
regimen (as identified in phase I) in untreated and poor responder PNH patients.105  
APL-2 (Apellis) 
Another compstatin analog is in development by Apellis; APL-2 is a pegylated version of the first-
generation compstatin POT-4, with possible long-lasting action. Initial safety and PK of APL-2 was 
investigated in 40 healthy volunteers enrolled in two phase I studies;107 two phase Ib studies for PNH 
patients are currently ongoing.108,109 A first study (Pharoah; NCT02264639) investigates APL-2 as add-
on therapy in PNH patients with inadequate response (defined as Hb level <10 g/L and/or need of red 
blood cell transfusion) to eculizumab.108 The second study (Paddock; NCT02588833) rather exploits 
APL-2 as single agent for untreated PNH patients with meaningful hemolysis (LDH >2x ULN).109 
APL-2 was used as daily SC infusions, at doses escalating up to 270 mg per day. The primary endpoint 
of both studies is safety; however preliminary efficacy was investigated as well, and even if full results 
are pending Apellis has disclosed some data.110 In all the 3 untreated PNH patients exploiting APL-2 as 
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single agent, a marked decline in LDH level was observed;110 in the 6 inadequate responders to 
eculizumab the add-on of APL-2 resulted in mild increase in hemoglobin and reduction in transfusion 
burden, with concomitant normalization of LDH.109 These data seem to support the concept that 
upstream interception of the complement cascade may impact both intravascular and extravascular 
hemolysis; however, more detailed information are needed to understand the possible role and the best 
use of APL-2 in PNH (e.g., monotherapy vs combined treatment, full vs subtotal C3 inhibition, 
possible bi-weekly dosing, etc.). While an extension treatment is ongoing, Apellis also announced that 
a phase III program for PNH will start soon.110    
ACH-0144471 (Achillion) 
 ACH-0144471 (also known as ACH-4471) was initially investigated in a Phase I study in 
healthy volunteers;111 ACH-4471 was given orally at single ascending doses. No major safety issue was 
raised; doses of 200-600 mg resulted in peak plasma level within a few (1-2) hours, with terminal half-
life of about 9 hours.111 Ex vivo evaluation of plasma CAP activity showed that pharmacological levels 
(IC90 was identified at 230 ng/mL) were achieved even after a single dose, eventually anticipating a bi-
daily dosing for therapeutic application.111 Based on these single- and double-dose data (and on another 
14-day multiple ascending dose trial in healthy volunteers), ACH-4471 has started its clinical 
translation in PNH, initially as single agent in untreated patients. A first trial investigating ascending 
doses was performed in New Zealand;112 data are not available, but an extension study is currently 
ongoing,113 eventually suggesting no major safety issue and possible efficacy.114 Another similar phase 
II proof-of-concept study in untreated patients has been recently launched in Europe, exploiting a fixed 
dose of 150 mg (possibly increased to 200 mg) three times a day; again here the primary endpoint 
includes the inhibition of intravascular hemolysis, as assessed by changes in LDH levels.115 In parallel, 
Achillion has also announced a phase II trial for PNH patients with inadequate response to eculizumab; 
this approach is somehow supported by in vitro data showing a possible synergism between ACH-4471 
and eculizumab.114 As for other upstream complement inhibitors, the anticipation is that ACH-4471 in 
the clinic should prevent both intravascular and extravascular hemolysis of PNH patients; whether the 
best approach is a monotherapy or a combination treatment will require further clinical investigations.  
LNP023 (Novartis)  
 A phase II trial with the anti-FB agent LNP023 for PNH has been announced by Novartis;116 
this study aims to investigate safety, PK, PD and efficacy of this FB inhibitor as add-on therapy in PNH 
patients showing residual hemolysis during eculizumab treatment.116 The study population includes 
PNH patients who have LDH >1.5x ULN (a marker of intravascular hemolysis) on stable doses of 
eculizumab.116 LNP023 will be given orally 200 mg bi-daily, based on results (not publically available) 
from a previous phase I study in healthy volunteers. This investigational treatment will be added on top 
of standard of care, defined as stable doses of eculizumab, in PNH patients. Notably, the primary 
endpoint of this study is improvement of hemolysis, which will be assessed based on changes in LDH 
plasma level (C3 deposition will be studied as well).116 Thus, both inclusion criteria and primary 
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endpoint address the issue of residual intravascular hemolysis during anti-C5 treatment, and may sound 
a little bit bizarre for an agent which has been designed to target C3-mediated extravascular hemolysis. 
Nevertheless, one may anticipate that, in case of therapeutic efficacy, the upstream inhibition of CAP 
will also prevent residual intravascular hemolysis, especially in combination with eculizumab. 
However, secondary endpoints may allow to explore the effect of LNP023 on possible C3-mediated 
extravascular hemolysis, hopefully to better understand the full potential of anti-FB agents as treatment 
for PNH, even in mono-therapy. 
 
Recommendations for future investigations  
What is the best way to improve the current anti-complement treatment of PNH? There is no complete 
agreement among experts in the field, and different strategies have been investigated; some of them 
seem to be driven also from financial interest of pharmaceutical companies rather than from robust 
scientific arguments. Nevertheless, the preliminary data described here, together with a deep 
understanding of the pathophysiology of PNH (and of real medical needs), may already allow to make 
conclusions about what we can expect from each strategy, and which ones may prevail in the long 
term. The majority of novel anti-C5 agents address the possibility to improve patients’ compliance with 
agents delivered with longer intervals, and/or in self-administration. Many of them also address the 
problem of intrinsic genetic resistance to eculizumab (even if we cannot exclude that different 
polymorphisms involving other C5 regions targeted by novel agents may eventually emerge). The next 
generation anti-C5 therapies aim to achieve a better control of intravascular hemolysis through a deeper 
inhibition of the terminal effector complement; this might be achieved also combining two distinct anti-
C5 agents, as also shown in vitro.23 Indeed, in some trials LDH normalization emerges as a primary 
endpoint, even if the clinical meaning of this biomarker remains to be proven. After more than 10 years 
of experience with eculizumab it is obvious that residual complement activity exist due to either PD 
(e.g., excess complement activation leading to massive C5 convertase generation, possibly favored by 
membrane-bound C3b)23 and/or PK reasons.24 Nevertheless, this quasi-complete C5 inhibition was 
sufficient to generate a great clinical benefit with minimal detrimental effect;2-7 future data will have to 
prove that a deeper C5 inhibition may result in a better hematological response and in a meaningful 
clinical benefit without carrying increased safety risk (e.g., infectious complications).87 Based on 
current understanding of PNH biology during anti-C5 treatment, complete functional knock-down of 
C5 should limit PD and PK breakthrough, with further reduction of intravascular hemolysis;87 however, 
no more than 15-20% of patients show laboratory signs of intravascular hemolysis which can benefit 
from this approach.24,117  
On the other hand, C3-extravascular hemolysis seems the most important factor limiting hematological 
efficacy of eculizumab, since even after LDH normalization on anti-C5 therapy most (if not all) PNH 
patients continue to show increased reticulocyte counts with a various degree of anemia.25-30 This 
pathogenic mechanism cannot be affected by any of the novel anti-C5 agents (even if used in 
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combination), and rather requires therapeutic interference upstream in the complement cascade. The 
possible impact of such upstream complement inhibition on safety needs to be carefully investigated; 
however, even if the theoretically increased risk of infectious complications requires specific attention, 
clinical observations from the few families carrying inherited deficiencies of complement genes118 
anticipate the feasibility of this approach. At this stage the two main strategies of anti-C3 and anti-
FD/FB inhibitors seem both equivalent in terms of possible efficacy. The obvious advantage of the oral 
administration of anti-FD/FB agents is somehow counterbalanced by the possible risk of hemolytic 
paroxysms due to activation through the CCP or the CMP (these are CAP-specific inhibitors), which 
would be prevented by broad C3 inhibitors. Furthermore, the preservation of some of the complement 
pathways may also represent a benefit in terms of reduced infectious risk. Even if these upstream 
inhibitors are in an earlier stage of development as compared to some novel anti-C5 agents (e.g., the 
long-acting ALXN1210 and SKY59), they anticipate to be the most active agents to ameliorate anemia 
in PNH. Indeed, such an endpoint, combined with sustained control of hemolysis, should become the 
clinical goal for next generation complement inhibitors. Of course, possible safety concerns, mostly 
infectious risk, might jeopardize the future of these agents. Likely, objective data will determine 
whether this strategy should be limited to patients with clinically meaningful C3-mediated 
extravascular hemolysis, or if it may have a broader use for all PNH patients. In this setting, the 
understanding of the complement cascade suggests that the complete inhibition of one key component 
of the cascade (e.g., C5, or C3, or FD/FB) should be enough to get the therapeutic effect. However, it 
has been also hypothesized that a sub-total inhibition of two key components (e.g., C3 or FB/FD in 
addition to C5) may result in similar clinical results, while preserving a minimal complement activity 
which could somehow mitigate safety concerns.119 Future clinical investigations will have to 
specifically address this possibility as well. 
 
Conclusions  
In summary, more than ten novel complement inhibitors are currently in development for PNH; 
different strategies have been exploited, each one with specific pros and cons (Table 2). Novel anti-C5 
agents promise to recapitulate the excellent results seen with eculizumab in terms of safety and 
efficacy, possibly improving the compliance to the treatment; furthermore, hematological benefit may 
be anticipated in some patients not achieving adequate control of intravascular hemolysis. On the other 
hand, upstream complement inhibitors targeting C3 or key molecules of the CAP (i.e., FD and FB) are 
developed aiming to control C3-mediated extravascular hemolysis, eventually anticipating a broader 
improvement in terms of hematological efficacy. Likely, these ongoing trials will not lead to the 
identification of a unique, perfect complement inhibitor recommended for all PNH patients. 
Nevertheless, if these trials will be adequately performed and coming data presented through standard 
peer-review process (rather than as pharmaceutical company announcements), hopefully these efforts 
will lead soon to the clinical availability of different novel complement inhibitors. In this future 
scenario, each agent might have a specific place in the treatment algorithm (possibly even tailored on 
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individual patients), eventually leading to a substantial improvement of the management of PNH. 
Hopefully, this achievement won’t be jeopardized by exaggerated of these novel agents; indeed, a 
broader worldwide access to appropriate treatment remains the most critical unmet need in the field of 
PNH.  
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FIGURE LEGEND 
 
Figure 1. The complement cascade and its targeted modulation. 
A. Overview of the complement cascade and of novel anti-complement agents.  
The three activating pathways (alternative, classical, and mannose/lectin) are individually depicted, 
together with the alternative pathway amplification loop.44 Candidate inhibitors are grouped according 
to their specific target; their modulatory effects are indicated by red lines intercepting specific steps of 
the complement cascade.31 Therapeutic interception of the complement cascade may occur: i. at the 
level of its common terminal effector pathway (e.g., C5); ii. at the level of its common key activation 
and amplification component (i.e., C3); iii. at the level of pathway-specific initiating events. For the 
purpose of PNH, for this latter target only the CAP is considered, since the role of CCP and CMP in the 
pathophysiology of PNH is considered somehow limited (even if experimental evidences are lacking). 
B. PNH pathogenic events eventually targeted by novel anti-complement agents. 
CAP inhibitors and C3 inhibitors both disable C3 activation, which results from C3 tick-over and in 
presence of therapeutic C5 inhibition leads to C3 opsonization of PNH erythrocytes. As a consequence, 
both CAP-inhibitors and C3 inhibitors anticipate therapeutic efficacy in preventing C3-mediated 
extravascular hemolysis. Mechanistically, this upstream inhibition should also prevent down-stream 
events of the terminal effector complement; indeed, intravascular hemolysis should be prevented as 
well. 
Novel C5 inhibitors disable the terminal effector complement, which usually result in intravascular 
hemolysis. In addition to represent an alternative to standard treatment eculizumab, these novel agents 
may result in a deeper C5 inhibition, eventually leading to the prevention of both pharmacokinetic and 
pharmacodynamics breakthrough possibly occurring during eculizumab treatment. 
 
 
Figure 2. Novel complement therapeutics towards their clinical translation. 
Graphical overview of the status of art of clinical translation for most relevant novel candidate 
complement therapeutics (from reference 35). The colors of the target indicate the phase of 
development (from preclinical work to marketing authorization): in white preclinical work (laboratory 
work or animal models); in light blue phase I trials (in healthy individuals or in PNH); in red phase II 
trials (in oterh indication or in PNH); in yellow phase III trial or marketing authorization. The target is 
divided in 4 quadrants which indicate the four most relevant classes of counds (based on their targets): 
upper left, inhibitors of the classical complement pathway (CCP); lower left, inhibitors of the classical 
alternative pathway (CAP); upper right, inhibitors of the complement component 5 (C5); lower right, 
inhibitors of the complement component 3 (C3). Each arrow indicates a specific agent with its stage of 
development (see main manuscript for detailed description). 
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Table 1. Candidate complement inhibitors in development for PNH and other complement-mediated diseases. 
 
Target Name Company Class of molecule Status of development Reff. 
C5 ALXN1210 Alexion Monoclonal antibody Active. Clinical (Phase III, PNH) 84-89 
C5 ALXN5500 Alexion Monoclonal antibody Active. Preclinical (PNH, unknown) 35 
C5 SKY59 Roche Monoclonal antibody Active. Clinical (Phase II, PNH) 38,90 
C5 ABP 959 Amgen Monoclonal antibody Active. Clinical (Phase III, PNH) 36,83 
C5 LFG 316 Novartis/Morphosys Monoclonal antibody Active. Clinical (Phase II, AMD and 
PNH) 
39 
C5 Mubodina® Adienne Monoclonal antibody 
(minibody) 
Active. Preclinical (non-PNH, TMAs) 40,41 
C5 Anti-C5 siRNA Alnylam si-RNA Active. Preclinical (non-PNH and 
PNH); clinical (Phase II, healthy 
volunteer and PNH) 
42,43,91-93 
C5 Coversin (OmCI) Akari Small animal protein 
(recombinant) 
Active. Preclinical (PNH); clinical 
(Phase II, healthy volunteers and PNH) 
44-47, 95-97 
C5 RA101348 Rapharma Small molecule (unnatural 
peptide) 
Active. Preclinical (unknown); clinical 
(PNH, phase II) 
48-50, 98-102 
C5 ARC1005 Novo Nordisk Aptamers  Active. Preclinical (non-PNH); clinical 
(Phase I, AMD) 
35 
C5 SOMAmers SomaLogic Aptamers (SELEX) Active. Preclinical (non-PNH) 35 
C5 SOBI002 Swedish Orphan Biovitrum 
(Affibody) 
Affibody (fused with albumin-
binding domain) 
Not active. Preclinical (non-PNH); 
clinical (Phase I, healthy volunteers) 
35 
C3 (C3b/iC3b) H17 EluSys Therapeutics Monoclonal antibody Not active. Preclinical (PNH and non-
PNH) 
55 
C3/C3b 4(1MeW)/POT-4 Potentia Compstatin family Not active. Preclinical (non-PNH); 
clinical (Phase I and II, AMD) 
56-58 
C3/C3b Cp40/AMY-101, PEG-
Cp40 
Amyndas Compstatin family Active. Preclinical (PNH and non-
PNH); clinical (Phase I, healthy 
volunteers and Phase II PNH, planned) 
56-61,105,106 
C3/C3b 4(1MeW)/APL-1, APL-
2 
Apellis Compstatin family Active. Preclinical (PNH and non-
PNH); clinical (Phase II, healthy 
volunteers and PNH) 
62,107-110 
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CFB TA106 Alexion Pharmaceuticals Monoclonal antibody Not active. Preclinical (unknown) 35 
CFD Lampalizumab 
(FCFD4514S) 
Genentech/Roche Monoclonal antibody Active. Preclinical (non-PNH); clinical 
(Phase II, AMD) 
35 
CFB Anti-FB siRNA Alnylam Si-RNA Not active. Preclinical (non-PNH) 35 
CFB and CFD SOMAmers SomaLogic Aptamers (SELEX) Not active. Preclinical (non-PNH) 35 
CFB LNP023   Novartis Small molecules (chemicals) Active. Clinical (PNH phase II) 81,82,116 
CFD n.a.   Novartis Small molecules (chemicals) Active. Preclinical (non-PNH) 77,78 
CFD ACH-3856 
ACH-4100 
ACH-4471 
Achillion Small molecules (chemicals) Active. Preclinical (PNH); clinical 
(Phase I, healthy volunteers and phase 
II PNH) 
79,80,111-115 
Properdin NM9401 Novelmed Monoclonal antibody (and 
mAb derivatives) 
Not active. Preclinical (unknown) 35,76 
C1s TNT003 True North Therapeutics Monoclonal antibody Active. Preclinical (CAD); clinical 
(Phase I, healthy volunteers and CAD) 
35 
MASP-1, MASP-2, 
MASP-3 
OMS721 (anti-MASP-
2) 
Omeros Monoclonal antibody Active. Preclinical (PNH and non-
PNH); clinical (TMAs and kidney 
disorders) 
35 
C1r/C1s Cinryze® Shire Human purified protein (C1-
INH) 
Active. Clinical (approved for 
Hereditary Angio-Edema) 
35 
CAP C3 convertase TT30 (CR2/CFH) Alexion CFH-based protein Active. Preclinical (PNH and non-
PNH); clinical (Phase I, PNH) 
69,104 
CAP C3 convertase Mini-FH Amyndas CFH-based protein Active. Preclinical (PNH and non-
PNH) 
70 
CAP C3 convertase Mini-FH n.a. CFH-based protein Not active. Preclinical (non-PNH) 35 
CAP C3 convertase CRIg/CFH n.a. CFH-based protein Not active. Preclinical 35 
CAP and CP C3 convertase sCR1 (CDX-1135) Celldex CR1-based protein Not active. Preclinical (non-PNH); 
clinical (Phase I, DDD) 
35 
CAP and CCP C3 
convertase 
Mirococept (APT070) n.a. CR1-based protein Active. Preclinical (non-PNH); clinical 
(Phase III, renal transplant) 
71-74 
CAP and CCP C3 
convertase 
TT32 (CR2/CR1) Alexion  CR1-based protein Not active. Preclinical (non-PNH) 35 
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Table 2. Ongoing clinical trials with novel complement inhibitors for PNH. 
 
Agent Target Clinical trial ID Design Patient population* Study treatment Primary endpoint 
ALXN1210 C5 N.A.33 Phase I, randomized vs placebo Healthy volunteers SAD, IV infusions Safety, PK and PD 
NCT0259858363 Phase I/II, open-label Untreated PNH Intra-patient DE by IV infusions Safety and efficacy (by LDH) 
NCT0260599364 Phase I/II, open-label Untreated PNH MAD; IV infusions Safety and efficacy (by LDH) 
NCT0294646367 Phase III, randomized vs Ecu Untreated PNH IV infusions (every 8 weeks) Efficacy (by LDH) 
NCT0305604068 Phase III, randomized vs Ecu Stable responders PNH IV infusions (every 8 weeks) Efficacy (by LDH) 
ABP 959 C5 ACTRN1261600050946062 Phase I, randomized vs Ecu Untreated PNH Single IV infusions PK similarity 
  EudraCT 2017-001418-2732 Phase III, randomized vs Ecu Stable responders PNH IV infusions Efficacy (LDH) 
SKY59 C5 NCT0315763569 Phase I/II, multi-part study Healthy volunteers SAD, IV infusions Safety, tolerability, PK and PD 
Untreated PNH Intra-patient  DE by IV infusions, 
followed by SC injections 
Safety, PD and efficacy 
Stable responders PNH Safety, PD and efficacy 
LFG316 C5 NCT0253490935 Phase II, open-label Untreated PNH IV infusions Efficacy (by LDH) 
ALNCC5 C5 NCT0235249370 Phase I/II, randomized vs Ecu, 
SAD and MAD 
Healthy volunteers SC injection Safety 
Untreated PNH SC injections Safety 
EudraCT 2016-002943-4073 Phase II, open-label Poor responder PNH (by LDH >2x 
ULN) 
SC injections Efficacy (by LDH) 
Coversin C5 N.A.39 Phase I, SAD and MD Healthy volunteers SC injections Safety, PK and PD 
NCT0259186274 Phase II, open-label Poor responder PNH (by LDH >1.5x 
ULN) 
SC injections; intra-patient DE Efficacy (by LDH) 
EudraCT 2016-002067-3375 Phase II, open-label, fixed dose Untreated PNH SC injections Efficacy (defined as LDH <1.5x ULN) 
EudraCT 2016-004129-1877 Phase II, open-label, extension PNH patients exposed to coversin SC injections Safety 
RA101495 C5 N.A.79,80 Phase I, SAD and MD Healthy volunteers Daily, SC injections Safety, PK and PD 
NCT0307858281 Phase II, open label, fixed dose Untreated PNH Daily, SC injections Efficacy (by LDH) 
Poor responders PNH (by LDH >2x 
ULN) 
NCT0303018382 Phase II, open label, fixed dose Poor responders PNH (by LDH 
>1.5x ULN) 
Daily, SC injections Efficacy (by LDH) 
NCT0322528783 Phase II, open-label, extension PNH patients exposed to RA101495 Daily, SC injections Safety 
TT30 CAP NCT0133516584 Phase I, SAD Untreated PNH SC injections and IV infusions Safety, PK and PD 
AMY-101 C3 NCT0331652187 Phase I, SAD and MD Healthy volunteers SC and IV infusions PK and PD 
N.A.86 Phase II, open label, fixed dose Untreated PNH Daily, SC infusions N.A. 
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N.A.86 Phase II, open label, fixed dose Poor responders PNH 
(moderate/severe anemia) 
Daily, SC infusions N.A. 
APL-2 C3 N.A.88 Phase I, SAD and MD Healthy volunteers SC and IV infusions Safety, PK and PD 
NCT0226463990 Phase Ib, open label, MAD, POC Poor responders PNH 
(moderate/severe anemia) 
Daily, SC infusions Safety and tolerability 
NCT0258883390 Phase Ib, open label, MAD, POC Untreated PNH Daily, SC infusions Safety and tolerability 
N.A.91 Phase II, open label, extension PNH patients exposed to APL-2 Daily, SC infusions N.A. 
ACH-4471 FD N.A.92 Phase I, SAD Healthy volunteers Orally, QD and BID Safety and tolerability 
NCT0318163393 Phase Ib, open label, MD, POC Untreated PNH Orally, BID Safety and efficacy (by LDH level) 
NCT0305310294 Phase II, open-label, extension PNH patients exposed to ACH-4471 Orally, BID Efficacy (by LDH level) 
EudraCT 2016-002652-2596 Phase II, open label, MD, POC Untreated PNH Orally, TID Efficacy (by LDH level) 
N.A.95 N.A. Poor responders PNH N.A. N.A. 
LNP023 FB EudraCT 2017-000888-3397 Phase II, open label Poor responders PNH (by LDH 
>1.5x ULN) 
Orally, BID Efficacy (by LDH level) 
 
*: stable or poor response is intended to standard eculizumab treatment; Abbreviations: N.A:: not available; Ecu: eculizumab; SAD: single ascending dose; MAD: multiple ascending 
doses; MD: multiple doses; POC: proof-of-concept; DE: dose escalation; SC: subcutaneous; IV: intravenous; QOD: quaque die (once a day); BID: bis in die (twice a day); TID: 
ter in die (thrice a day); PK: pharmacokinetics; PD: pharmacodynamics; LDH: lactate dehydrogenase 
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Table 3. Anticipated pros and cons of novel complement inhibitors in development for PNH. 
 
Company 
          
Name ALXN1210 LFG316 SKY59 RA101495 ALNCC5 Coversin AMY-101 APL-2 ACH-4471 LNP023 
EFFICACY 
C5-
polymorphism 
No Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Breakthrough 
intravascular 
hemolysis 
Yes ++ N.A. Yes + Yes +(§) Yes +++§ Yes +(§) (Yes ++[§]) (Yes ++[§]) (Yes ++[§]) (Yes ++[§]) 
C3-mediated 
extravascular 
hemolysis 
No No No No No No (Yes +++) (Yes +++) (Yes +++) (Yes +++) 
Marrow failure No No No No No No No No No No 
Monotherapy* Yes +++ Yes +++ Yes +++ Yes ++ No Yes + Yes ++ Yes ++ (Yes +) (Yes +) 
SAFETY 
Off-targets No No No No No No (No) (No) (No) (No) 
Immunogenicity No No No (No) No Yes + (No) (No) (No) (No) 
Infectious risk° Yes + (No) Yes + (No) Yes ++ (No) (Yes ++) (Yes ++) (Yes ++) (Yes ++) 
Autoimmune 
complications 
No No No No No No ? ? ? ? 
Breakthrough 
due to missed 
doses 
No No No Yes + No Yes + (Yes +) (Yes +) (Yes ++) (Yes ++) 
Breakthrough 
due to CCP 
activation 
No No No No No No No No Yes +++ Yes +++ 
COMPLIANCE 
Adm. route IV IV IV and SC SC SC SC SC (infusion) SC (infusion) Orally Orally 
Frequency# 8 weeks 2 weeks 1-2-4 weeks Daily 4-8 weeks? Daily Daily Daily TID TID 
Self-
administration 
No No No Yes No Yes Yes Yes Yes Yes 
COST-EFFECTIVENESS 
Possible price +++ ? + ? +++ ? ++ ? +++ ? ++ ? + ? +++ ? ++ ? ++ ? 
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Statements in parenthesis are based preclinical data but still lack full confirmation from clinical trials; §: in combination with eculizumab; *: the possibility of monotherapy is based on available data and current trials rather 
than on theoretical assumptions; °: the infectious risk (as compared to eculizumab treatment) is based on the specific target, the deepness of inhibition and on the possibility to easily rescue complement activity by treatment 
stopping; IV: intravenous; SC: subcutaneous; #: frequency during maintenance treatment; BID: bis in die (twice a day); TID: ter in die (thrice a day). 
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